Simon Jones
Direttore Finanziario/CFO presso Karus Therapeutics Ltd.
Profilo
Simon Jones is currently working as a Director at OMERS Private Equity Europe Ltd.
and also holds positions at TH Global Ltd.
and Karus Therapeutics Ltd.
He previously worked as a Principal at Vodafone UK Ltd.
and as a Chief Financial Officer at Oxonica Ltd.
and Glide Pharmaceutical Technologies Ltd.
Mr. Jones completed his undergraduate degree at the University of Warwick.
Posizioni attive di Simon Jones
Società | Posizione | Inizio |
---|---|---|
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Direttore Finanziario/CFO | - |
OMERS Private Equity Europe Ltd. | Investitore di Private Equity | 01/03/2010 |
Precedenti posizioni note di Simon Jones
Società | Posizione | Fine |
---|---|---|
Oxonica Ltd.
Oxonica Ltd. Miscellaneous Commercial ServicesCommercial Services Oxonica Ltd. is an advanced materials business, which engages in licensing of patents related to nanomaterials. The company was founded in 1999 and is headquartered in Birmingham, the United Kingdom. | Direttore Finanziario/CFO | - |
Vodafone UK Ltd.
Vodafone UK Ltd. Wireless TelecommunicationsCommunications Vodafone UK Ltd. provides mobile telecommunications services. Its services include information on services, pricing, roaming, and coverage. Its subscribers include corporate and individual consumers. Vodafone has launched 3G service in the 2004 and is responsible for wireless operations of Vodafone Group in UK. The company is headquartered in Newbury, UK. | Corporate Officer/Principal | - |
Glide Pharmaceutical Technologies Ltd.
Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom. | Direttore Finanziario/CFO | 29/03/2013 |
Formazione di Simon Jones
University of Warwick | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 5 |
---|---|
Vodafone UK Ltd.
Vodafone UK Ltd. Wireless TelecommunicationsCommunications Vodafone UK Ltd. provides mobile telecommunications services. Its services include information on services, pricing, roaming, and coverage. Its subscribers include corporate and individual consumers. Vodafone has launched 3G service in the 2004 and is responsible for wireless operations of Vodafone Group in UK. The company is headquartered in Newbury, UK. | Communications |
Oxonica Ltd.
Oxonica Ltd. Miscellaneous Commercial ServicesCommercial Services Oxonica Ltd. is an advanced materials business, which engages in licensing of patents related to nanomaterials. The company was founded in 1999 and is headquartered in Birmingham, the United Kingdom. | Commercial Services |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Glide Pharmaceutical Technologies Ltd.
Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom. | Health Technology |
OMERS Private Equity Europe Ltd. | Finance |
- Borsa valori
- Insiders
- Simon Jones